Nebenwirkungen · Afstyla
AFSTYLA 250 IU powder and solvent for solution for injection AFSTYLA 500 IU powder and solvent for solution for injection AFSTYLA 1000 IU powder and solvent for solution for injection AFSTYLA 1500 IU powder and solvent for solution for injection AFSTYLA 2000 IU powder and solvent for solution for injection AFSTYLA 2500 IU powder and solvent for solution for injection AFSTYLA 3000 IU powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 7
HOS-134706 · Präparat HOS-097594
MedDRA Adverse reaction Frequency System Organ Class uncommon (PTPs)* Blood and lymphatic FVIII inhibition very common system disorders (PUPs)* Immune system disorders Hypersensitivity common Nervous system disorders Dizziness common Paraesthesia common Skin and subcutaneous Rash common tissue disorders Erythema uncommon Pruritus uncommon General disorders and Pyrexia common administration site Injection site pain uncommon conditions Chills uncommon Feeling hot uncommon *Frequency is based on studies with all FVIII products which included patients with severe haemophilia A. PTPs = previously-treated patients, PUPs = previously-untreated patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-16T14:40:00Z · SHA-256 16ec7d420a0e09bb5f20f98483f709a76e364615274fa2d524545f907057147d · Passage ba5f9e06730c5895168c8d932e114e1de53afc35fbb6c8fbd42a3cd945ce2d89 · Zeichen 1349–2664 im Abschnitt